TKI

MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)

Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease

Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy

Stereotactic Body Radiotherapy for the Treatment of OPD

Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer

HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure

Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial

TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients

A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs

Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma

A Study on the Withdrawal of Second-generation Tyrosine Kinase Inhibitors After Dose Reduction in Patients With CML

Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC

MWA With or Without Furmonertinib for Early-Stage Non-Small Cell Lung Cancer

CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC